Host-driven antibody responses against Staphylococcus aureus

NIH RePORTER · NIH · R21 · $246,000 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Staphylococcus aureus is a human-adapted pathogen that replicates by asymptomatically colonizing its host. S. aureus is also the causative agent of purulent skin and soft tissue infections as well as bloodstream infections that result in the metastatic seeding of abscess lesions in all organ tissues. A hallmark of infection and colonization is recurrence, a phenomenon that reflects both a failure of the host to generate protective immunity and the highly versatile capacity of this pathogen to surmount innate and adaptive immune defenses. As a consequence, approaches to identify the protective antigens of S. aureus to develop a successful vaccine have failed, leading to the notion that staphylococcal-neutralizing adaptive responses may not be sufficient to reduce burdens imposed by this pathogen. Here, we find that this might not always be the case. Mice lacking functional H2-O (the equivalent of human HLA-DO) inoculated with a mouse-adapted strain of S. aureus efficiently de-colonized the pathogen. De-colonized mice resisted bloodstream challenge with the MRSA isolate USA300 suggesting that they were immune to the pathogen. We found that T-cell dependent B cell responses were required to control S. aureus colonization in H2-O-deficient mice and that H2-O-deicient mice produced higher titer S. aureus-specific antibodies compared to wild-type mice. H2-O is a negative regulator of MHC-II peptide loading and presentation and was shown to restrict the loading of high affinity peptides. Thus, we hypothesize that the muted immune responses against S. aureus are derepressed in mice lacking H2-O. We propose to exploit this observation and identify S. aureus-immunodominant antigens and -specific T cells and B cells as well as antibody sub-classes that lead to decolonization of the pathogen.

Key facts

NIH application ID
10986215
Project number
1R21AI181332-01A1
Recipient
UNIVERSITY OF CHICAGO
Principal Investigator
Tatyana V Golovkina
Activity code
R21
Funding institute
NIH
Fiscal year
2024
Award amount
$246,000
Award type
1
Project period
2024-07-12 → 2026-05-31